## Francois Vermeulen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8283776/publications.pdf

Version: 2024-02-01

516681 395678 2,033 35 16 33 citations g-index h-index papers 36 36 36 2718 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet, The, 2019, 394, 1940-1948.	13.7	804
2	Coronavirus disease 2019 in patients with inborn errors of immunity: An international study. Journal of Allergy and Clinical Immunology, 2021, 147, 520-531.	2.9	278
3	Ataluren (PTC124) Induces Cystic Fibrosis Transmembrane Conductance Regulator Protein Expression and Activity in Children with Nonsense Mutation Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2010, 182, 1262-1272.	5.6	231
4	Lung clearance index predicts pulmonary exacerbations in young patients with cystic fibrosis. Thorax, 2014, 69, 39-45.	5.6	77
5	Correction of CFTR function in intestinal organoids to guide treatment of cystic fibrosis. European Respiratory Journal, 2021, 57, 1902426.	6.7	71
6	The diagnosis of cystic fibrosis. Presse Medicale, 2017, 46, e97-e108.	1.9	64
7	Impact of Air Pollution on Cystic Fibrosis Pulmonary Exacerbations. Chest, 2013, 143, 946-954.	0.8	60
8	An International Randomized Multicenter Comparison of Nasal Potential Difference Techniques. Chest, 2010, 138, 919-928.	0.8	50
9	Liver disease in cystic fibrosis presents as non-cirrhotic portal hypertension. Journal of Cystic Fibrosis, 2017, 16, e11-e13.	0.7	48
10	The impact of the COVID-19 pandemic on the emotional well-being and home treatment of Belgian patients with cystic fibrosis, including transplanted patients and paediatric patients. Journal of Cystic Fibrosis, 2020, 19, 880-887.	0.7	38
11	Nasal potential difference measurements in diagnosis of cystic fibrosis: An international survey. Journal of Cystic Fibrosis, 2014, 13, 24-28.	0.7	34
12	Human DOCK2 Deficiency: Report of a Novel Mutation and Evidence for Neutrophil Dysfunction. Journal of Clinical Immunology, 2019, 39, 298-308.	3.8	31
13	Fifth Percentile Cutoff Values for Antipneumococcal Polysaccharide and Anti-Salmonella typhi Vi IgG Describe a Normal Polysaccharide Response. Frontiers in Immunology, 2017, 8, 546.	4.8	29
14	Complicated parapneumonic effusion in Belgian children: increased occurrence before routine pneumococcal vaccine implementation. European Journal of Pediatrics, 2009, 168, 51-58.	2.7	25
15	Reference Values for Central Airway Dimensions on CT Images of Children and Adolescents. American Journal of Roentgenology, 2018, 210, 423-430.	2.2	24
16	Chronic Aichi Virus Infection in a Patient with X-Linked Agammaglobulinemia. Journal of Clinical Immunology, 2018, 38, 748-752.	3.8	18
17	Rectal organoid morphology analysis (ROMA) as a promising diagnostic tool in cystic fibrosis. Thorax, 2021, 76, 1146-1149.	5.6	17
18	Novel CFTR modulator combinations maximise rescue of G85E and N1303K in rectal organoids. ERJ Open Research, 2022, 8, 00716-2021.	2.6	17

#	Article	IF	CITATIONS
19	Nasal potential measurements on the nasal floor and under the inferior turbinate: Does it matter?. Pediatric Pulmonology, 2011, 46, 145-152.	2.0	15
20	Clinical outcome of parapneumonic empyema in children treated according to a standardized medical treatment. European Journal of Pediatrics, 2014, 173, 1339-1345.	2.7	14
21	The longâ€ŧerm outcome of an isolated vascular ring – A singleâ€center experience. Pediatric Pulmonology, 2019, 54, 2028-2034.	2.0	13
22	Assays of CFTR Function In Vitro, Ex Vivo and In Vivo. International Journal of Molecular Sciences, 2022, 23, 1437.	4.1	13
23	Mild humoral immunodeficiency in a patient with Xâ€linked Kabuki syndrome. American Journal of Medical Genetics, Part A, 2016, 170, 801-803.	1.2	11
24	Defining Polysaccharide Antibody Deficiency: Measurement of Anti-Pneumococcal Antibodies and Anti-Salmonella typhi Antibodies in a Cohort of Patients with Recurrent Infections. Journal of Clinical Immunology, 2020, 40, 105-113.	3.8	9
25	Influence of perfusate temperature on nasal potential difference. European Respiratory Journal, 2013, 42, 389-393.	6.7	7
26	Improved repeatability of nasal potential difference with a larger surface catheter. Journal of Cystic Fibrosis, 2015, 14, 317-323.	0.7	7
27	Lung function evolution in children with old and new type bronchopulmonary dysplasia: a retrospective cohort analysis. European Journal of Pediatrics, 2019, 178, 1859-1866.	2.7	7
28	Isolation of Enterobacteriaceae in airway samples is associated with worse outcome in preschool children with cystic fibrosis. Journal of Cystic Fibrosis, 2020, 19, 365-369.	0.7	5
29	Riociguat for the treatment of Phe508del homozygous adults with cystic fibrosis. Journal of Cystic Fibrosis, 2021, 20, 1018-1025.	0.7	5
30	Comparison of lung clearance index measured during helium washin and washout in children with cystic fibrosis. Pediatric Pulmonology, 2013, 48, 962-969.	2.0	3
31	How to approach complications of acute rhinosinusitis in children?. International Journal of Pediatric Otorhinolaryngology, 2020, 136, 110155.	1.0	3
32	Chest CT scoring for evaluation of lung sequelae in congenital diaphragmatic hernia survivors. Pediatric Pulmonology, 2020, 55, 740-746.	2.0	3
33	Clinical characteristics of patients with low functional IL-6 production upon TLR/IL-1R stimulation. Journal of Allergy and Clinical Immunology, 2018, 141, 768-770.	2.9	0
34	The use of chest CT scan in evaluation of structural lung sequelae in congenital diaphragmatic hernia survivors. , $2017, \dots$		0
35	Multiple breath washout measurement in patients with CDH at school age compared to Chest CT score and spirometry. , 2020, , .		0